Echosens Ranks Among PM360’s Leading Innovative Companies for 9th Annual Innovations Issue, Demonstrates Ingenuity During COVID-19 Pandemic
“Our industry didn’t waste a second in working to address how COVID-19 impacted patients, healthcare professionals and the way companies were forced to operate,” says Anna Stashower, CEO, publisher, and editor-in-chief, PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device and diagnostics industries. “This year’s selections are not just a highlight of our industry’s incredible ingenuity, but also the efficiency and determination they demonstrated in response to a world in crisis. Even though not all of our selections are related to COVID-19, they all show just how hard our industry works to find new, better and quicker ways to improve how the industry operates to better serve patients.”
FibroScan uses a patented technique called VCTE in which a controlled frequency shear wave is mechanically induced to the liver. In 2020, Echosens introduced FibroScan 630 Expert to give clinicians the capability to measure spleen stiffness. Non-invasive assessment of the spleen is an important advancement in assessing portal hypertension (PH), which is the main consequence of cirrhosis and responsible for a majority of its complications. In the western world, the most common etiology of PH is cirrhosis due to alcoholic liver disease, nonalcoholic steatohepatitis (NASH), and hepatitis C infection. According to a recent estimate 15 million people in the United States have alcohol abuse disorder, nearly 88,000 people die annually due to alcohol, 10%-15% of people with alcoholism develop cirrhosis, and another 3 million people have chronic hepatitis C infection, with 25%-28% of these patients developing cirrhosis.
Jon Gingrich, CEO, Echosens North America, says, “We are thrilled to be included in this impressive list of innovators by PM360, a publication that has always recognized how crucial innovation is within this industry. This honor further validates our efforts to provide non-invasive tools that enable clinicians to battle the nation’s liver disease epidemic.”
Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans. For more information, please visit http://www.echosens.us.
201.641.1911 x 14